retatrutide trial weight loss Experimental drug shows promising results in Phase-3-Retatrutide-trial-sees-participants-achieve-up-to-30-weight-loss

According to research published in The New England Journal of Medicine [3], participants receiving higher doses achieved up to 17.5% weight loss at 24 weeks and 24.2% at 48 weeks

In this context, we note that the remarkable effects of GLP-1RAs in achieving weight loss may fail to be maintained over the long term once medications are stopped 247

Those with a history of disordered eating should proceed with caution and work closely with their doctor and therapist as they consider the pros and cons of semaglutide

INCRETINS Release from the gut of incretin hormones (GIP and GLP-1) is responsible for amplification of insulin secretion, which occurs when nutrients are taken orally rather than being infused intravenously [1]

These drugs help manage type 2 diabetes by increasing insulin production and decreasing glucagon release, improving blood sugar control and cardiovascular health